FAST - A study to evaluate the efficacy and safety of quetiapin[e] IR in patients with acute psychosis.

Trial Profile

FAST - A study to evaluate the efficacy and safety of quetiapin[e] IR in patients with acute psychosis.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 21 Jul 2011

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Psychotic disorders
  • Focus Therapeutic Use
  • Acronyms FAST-A
  • Sponsors AstraZeneca
  • Most Recent Events

    • 09 Dec 2010 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
    • 23 Apr 2008 Status changed from recruiting to discontinued, reported by ClinicalTrials.
    • 23 Nov 2007 The expected completion date for this trial is now 1 Apr 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top